This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $38.87, marking a -0.15% move from the previous day.
Aerie's (AERI) Application for Roclanda Accepted in Europe
by Zacks Equity Research
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
Horizon Therapeutics' Stock Up in a Year on Pipeline Progress
by Zacks Equity Research
Horizon Therapeutics' (HZNP) shares have risen in the past year owing to the development of its pipeline candidates.
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
by Zacks Equity Research
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
The Zacks Analyst Blog Highlights: Pfizer, BP, Fidelity National Information Services, Deere & Company and Equity Residential
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BP, Fidelity National Information Services, Deere & Company and Equity Residential
3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
by Zacks Equity Research
Here are three reasons, which investors may consider while investing in Lilly's (LLY) stock.
The Zacks Analyst Blog Highlights: Exxon Mobil, Verizon, Chevron, Pfizer and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Verizon, Chevron, Pfizer and 3M
Top Stock Reports for Pfizer, BP & Fidelity National Information Services
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), BP p.l.c. (BP) and Fidelity National Information Services (FIS).
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $39.16, marking a +0.64% move from the previous day.
AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
5 Dogs of the Dow for 2020
by Tirthankar Chakraborty
It may be all bark and no bite for Dogs of the Dow in 2019. But 2020 holds promise for them.
Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline
by Zacks Equity Research
Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.
Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?
by Zacks Equity Research
As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.
Pfizer (PFE) Sees a Difficult 2019: Can it Rebound in 2020?
by Zacks Equity Research
Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.
Epizyme (EPZM) Shares Soar on Lead Candidate's Progress
by Zacks Equity Research
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $39.32 in the latest trading session, marking a +0.23% move from the prior day.
GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA
by Zacks Equity Research
GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.
Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication
by Zacks Equity Research
The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs
by Kinjel Shah
Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
Pfizer's Braftovi sNDA Accepted by FDA for Priority Review
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $38.90 in the latest trading session, marking a -0.61% move from the prior day.
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Group
by Zacks Equity Research
With data from the ARCHES study approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe
by Zacks Equity Research
Pfizer (PFE) receives a positive CHMP opinion recommending approval for once-daily Vyndaqel (61mg) oral capsule to treat hereditary transthyretin amyloid cardiomyopathy in adult patients.